Literature DB >> 27067546

Multifaceted enrichment analysis of RNA-RNA crosstalk reveals cooperating micro-societies in human colorectal cancer.

Tommaso Mazza1, Gianluigi Mazzoccoli2, Caterina Fusilli3, Daniele Capocefalo3, Anna Panza4, Tommaso Biagini3, Stefano Castellana3, Annamaria Gentile4, Angelo De Cata5, Orazio Palumbo6, Raffaella Stallone6, Rosa Rubino5, Massimo Carella6, Ada Piepoli7.   

Abstract

Alterations in the balance of mRNA and microRNA (miRNA) expression profiles contribute to the onset and development of colorectal cancer. The regulatory functions of individual miRNA-gene pairs are widely acknowledged, but group effects are largely unexplored. We performed an integrative analysis of mRNA-miRNA and miRNA-miRNA interactions using high-throughput mRNA and miRNA expression profiles obtained from matched specimens of human colorectal cancer tissue and adjacent non-tumorous mucosa. This investigation resulted in a hypernetwork-based model, whose functional backbone was fulfilled by tight micro-societies of miRNAs. These proved to modulate several genes that are known to control a set of significantly enriched cancer-enhancer and cancer-protection biological processes, and that an array of upstream regulatory analyses demonstrated to be dependent on miR-145, a cell cycle and MAPK signaling cascade master regulator. In conclusion, we reveal miRNA-gene clusters and gene families with close functional relationships and highlight the role of miR-145 as potent upstream regulator of a complex RNA-RNA crosstalk, which mechanistically modulates several signaling pathways and regulatory circuits that when deranged are relevant to the changes occurring in colorectal carcinogenesis.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27067546      PMCID: PMC4872111          DOI: 10.1093/nar/gkw245

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  51 in total

1.  Sizing up miRNAs as cancer genes.

Authors:  Carlos Caldas; James D Brenton
Journal:  Nat Med       Date:  2005-07       Impact factor: 53.440

2.  Improved scoring of functional groups from gene expression data by decorrelating GO graph structure.

Authors:  Adrian Alexa; Jörg Rahnenführer; Thomas Lengauer
Journal:  Bioinformatics       Date:  2006-04-10       Impact factor: 6.937

3.  Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors.

Authors:  Keith Woods; J Michael Thomson; Scott M Hammond
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

4.  An E2F/miR-20a autoregulatory feedback loop.

Authors:  Yannick Sylvestre; Vincent De Guire; Emmanuelle Querido; Utpal K Mukhopadhyay; Véronique Bourdeau; François Major; Gerardo Ferbeyre; Pascal Chartrand
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

Review 5.  Genomics of microRNA.

Authors:  V Narry Kim; Jin-Wu Nam
Journal:  Trends Genet       Date:  2006-01-30       Impact factor: 11.639

6.  MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  Oncol Rep       Date:  2006-10       Impact factor: 3.906

7.  Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma.

Authors:  C M Wright; O F Dent; R C Newland; M Barker; P H Chapuis; E L Bokey; J P Young; B A Leggett; J R Jass; G A Macdonald
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 8.  Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.

Authors:  Delphine Javelaud; Alain Mauviel
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

9.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

10.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations.

Authors:  Yang Li; Chengxiang Qiu; Jian Tu; Bin Geng; Jichun Yang; Tianzi Jiang; Qinghua Cui
Journal:  Nucleic Acids Res       Date:  2013-11-04       Impact factor: 16.971

View more
  5 in total

1.  Analysis of clock gene-miRNA correlation networks reveals candidate drivers in colorectal cancer.

Authors:  Gianluigi Mazzoccoli; Tommaso Colangelo; Anna Panza; Rosa Rubino; Cristiana Tiberio; Orazio Palumbo; Massimo Carella; Domenico Trombetta; Annamaria Gentile; Francesca Tavano; Maria Rosa Valvano; Clelia Tiziana Storlazzi; Gemma Macchia; Angelo De Cata; Giovanni Bisceglia; Daniele Capocefalo; Vittorio Colantuoni; Lina Sabatino; Ada Piepoli; Tommaso Mazza
Journal:  Oncotarget       Date:  2016-07-19

2.  Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis.

Authors:  Zhibin Liao; Hongwei Zhang; Chen Su; Furong Liu; Yachong Liu; Jia Song; He Zhu; Yawei Fan; Xuewu Zhang; Wei Dong; Xiaoping Chen; Huifang Liang; Bixiang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-23

3.  Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.

Authors:  Danyang Wang; Qingmin Liu; Yanjun Ren; Yan Zhang; Xin Wang; Bing Liu
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

4.  Integrative analysis of TCGA data identifies miRNAs as drug-specific survival biomarkers.

Authors:  Shuting Lin; Jie Zhou; Yiqiong Xiao; Bridget Neary; Yong Teng; Peng Qiu
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

5.  MAFA-AS1, a long non-coding RNA, predicts for poor survival of hepatocellular carcinoma.

Authors:  Yuting Zhan; Xin-Yuan Guan; Yan Li
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.